Literature DB >> 19243546

Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes.

Abdul Tawab1, Yong Fan, Elizabeth J Read, Roger J Kurlander.   

Abstract

BACKGROUND: To generate clinical-grade dendritic cells (DCs) ex vivo for immunotherapy trials, peripheral blood monocytes are typically cultured in granulocyte-macrophage-colony-stimulating factor (GM-CSF) and interleukin (IL)-4 and then matured using one or more agents. Duration of the initial DC culture is one important variable that has not been systematically evaluated for its effect on the characteristics of the final mature DC product. STUDY
DESIGN: DCs were generated from elutriated peripheral blood monocytes by incubation in medium containing 2000 units per mL each of GM-CSF and IL-4 for 3 to 7 days, followed by maturation with lipopolysaccharide and interferon-gamma (IFN-gamma). DC yield, viability, flow cytometric phenotype, and cytokine production were evaluated.
RESULTS: The percentage yield and viability of mature DCs were similar after GM-CSF/IL-4 culture for 3 or 7 days. In either case, mature DCs expressed abundant CD80, CD86, CD83, and CCR7, but 3-day DCs expressed these antigens in a more consistent and homogeneous manner. Mature 3-day DCs produced much more IL-12 and less IL-10 after restimulation with CD40L-LTK than 7-day DCs. The former were also more effective in presenting immunogenic peptides to CD8 T cells. Analogous changes in cytokine production were observed in mature DCs prepared using lower concentrations of GM-CSF/IL-4 or when the alternative maturation cocktails poly(I:C)/IFN-gamma and soluble CD40L/IFN-gamma were used.
CONCLUSION: Extended initial culture of DCs in GM-CSF/IL-4 does not affect yield or viability of subsequently matured DCs, but can adversely affect their ability to homogeneously express high levels of functionally important surface molecules such as CD83 and CCR7 and to produce IL-12.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243546      PMCID: PMC3859301          DOI: 10.1111/j.1537-2995.2008.02020.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  37 in total

1.  Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.

Authors:  Marc Dauer; Bianca Obermaier; Jan Herten; Carola Haerle; Katrin Pohl; Simon Rothenfusser; Max Schnurr; Stefan Endres; Andreas Eigler
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.

Authors:  Shuwen Xu; Gary K Koski; Mark Faries; Isabelle Bedrosian; Rosemarie Mick; Markus Maeurer; Martin A Cheever; Peter A Cohen; Brian J Czerniecki
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

Review 3.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

4.  Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12.

Authors:  Redouane Rouas; Philippe Lewalle; Frank El Ouriaghli; Berengere Nowak; Hughes Duvillier; Philippe Martiat
Journal:  Int Immunol       Date:  2004-03-29       Impact factor: 4.823

5.  Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.

Authors:  E C Wong; V E Maher; K Hines; J Lee; C S Carter; T Goletz; W Kopp; C L Mackall; J Berzofsky; E J Read
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

6.  Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.

Authors:  J Babatz; C Röllig; U Oelschlägel; S Zhao; G Ehninger; M Schmitz; M Bornhäuser
Journal:  J Hematother Stem Cell Res       Date:  2003-10

7.  Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.

Authors:  Zhen Su; Johannes Vieweg; Alon Z Weizer; Philipp Dahm; Donna Yancey; Vandana Turaga; John Higgins; David Boczkowski; Eli Gilboa; Jens Dannull
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 8.  The use of dendritic cells in cancer immunotherapy.

Authors:  Gerold Schuler; Beatrice Schuler-Thurner; Ralph M Steinman
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

9.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming.

Authors:  Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  9 in total

1.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

2.  Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.

Authors:  Mei Zhu; Wei Xu; Hong Su; Qiong Huang; Baolong Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Tolerogenic dendritic cells and their role in transplantation.

Authors:  Mohamed Ezzelarab; Angus W Thomson
Journal:  Semin Immunol       Date:  2011-07-07       Impact factor: 11.130

Review 4.  Dendritic cell-based immunity and vaccination against hepatitis C virus infection.

Authors:  Yun Zhou; Ying Zhang; Zhiqiang Yao; Jonathan Patrick Moorman; Zhansheng Jia
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

5.  IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.

Authors:  Huifeng Yu; Abdul Tawab-Amiri; Amiran Dzutsev; Marianna Sabatino; Karen Aleman; Robert Yarchoan; Masaki Terabe; Yongjun Sui; Jay A Berzofsky
Journal:  J Leukoc Biol       Date:  2011-04-07       Impact factor: 4.962

6.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

Authors:  Sébastien Anguille; Evelien L J M Smits; Nathalie Cools; Herman Goossens; Zwi N Berneman; Vigor F I Van Tendeloo
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

7.  IL-15 Generates IFN-γ-producing Cells Reciprocally Expressing Lymphoid-Myeloid Markers during Dendritic Cell Differentiation.

Authors:  Kee Woong Kwon; So Jeong Kim; Hongmin Kim; Woo Sik Kim; Soon Myung Kang; Eunsol Choi; Sang-Jun Ha; Joo-Heon Yoon; Sung Jae Shin
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

8.  A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice.

Authors:  Akira Kodama; Reiko Tanaka; Mineki Saito; Aftab A Ansari; Yuetsu Tanaka
Journal:  Front Microbiol       Date:  2013-09-27       Impact factor: 5.640

9.  Generating Bovine Monocyte-Derived Dendritic Cells for Experimental and Clinical Applications Using Commercially Available Serum-Free Medium.

Authors:  Jack Guinan; Brina S Lopez
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.